Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 516-522

  Ng, Chee ^a   Sarris, Jerome ^a,b   Singh, Ajeet ^c   Bousman, Chad ^a,b   Byron, Keith ^d   Peh, Lai Huat ^e   Smith, Deidre Joy ^a   Tan, Chay Hoon ^f   Schweitzer, Isaac ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d Healthscope Pathology   (Australia)

^e CHANGI GENERAL HOSPITAL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

ethnopsychopharmacology; personalized medicine; pharmacogenomic

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; ESCITALOPRAM; VENLAFAXINE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HAMILTON SCALE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE;

ETHNOPSYCHOPHARMACOLOGY; PERSONALIZED MEDICINE; PHARMACOGENOMIC;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CITALOPRAM; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SINGLE-BLIND METHOD; TIME FACTORS; YOUNG ADULT;

EID: 84884142524     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2340     Document Type: Article

References (20)

1. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders (4th 'Text Revision' edn). American Psychiatric Association: Arlington.
2. Guy W, Bonato R,. 1970. CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery (Revised). National Institute of Mental Health: Chevy Chase, MD.
3. Hamilton M,. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
4. Huezo-Diaz P, Uher R, Smith R, et al,. 2009. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195: 30-38.
5. Kim DK, Lim SW, Lee S, et al,. 2000. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11: 215-219.
6. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K,. 2000. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50: 31-4.
7. Lingjaerde O, Ahlfors UG, Bech P, et al,. 1987. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334: 1s-100s.
8. Min W, Li T, Ma X, et al,. 2009. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 205: 409-417.
9. Ng CH, Schweitzer I, Norman T, Easteal S,. 2004. The emerging role of pharmacogenetics: Implications for clinical psychiatry. Aust N Z J Psychiatry 38: 483-489.
10. Ng CH, Chong SA, Lambert T, Fan A, Hackett LP, Mahendran R,. 2005. An interethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 20: 163-168.
11. Ng C, Easteal S, Tan S, Schweitzer I, Ho B, Aziz S,. 2006a. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Progr Neuro Psychopharmacol Biol Psychiatr 30: 953-957.
12. Ng CH, Norman TR, Naing KO, et al,. 2006b. A comparison study of sertraline dosages and response in Chinese versus Caucasian patients. Int Clin Psychopharmacol 21: 87-92.
13. Poolsup N, Li WP, Knight TL,. 2000. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther 197: 197-220.
14. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati, R, Serretti A,. 2011. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36: 87-113.
15. Porcelli S, Fabbri C, Serretti A,. 2012. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22: 239-258.
16. Preskorn SH,. 1997. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32 (suppl 1): 1-21.
17. Serretti A, Kato M, de Ronchi D, et al,. 2007. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12: 247-257.
18. Vermeiden M, van den Broek WW, Mulder PG, Birkenhäger TK,. Influence of gender and menopausal status on antidepressant treatment response in depressed inpatients. J Psychopharmacol 2010; 24 (4): 497-502.
19. Wilkie MJV, Smith G, Day RK, et al,. 2009. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 9: 61-70.
20. Yoshida K, Ito K, Sato K, et al,. 2002. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Progr Neuro Psychopharmacol Biol Psychiatr 26: 383-386.